Beam Therapeutics

NSQ:BEAM · US07373V1052

BiotechnologySmall

360

Value46

Profit price95

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price35

Price/Sales28

Price/Book41

Quality43

Returns on capital64

Return on Capital49

Cash Return on Capital72

Return on Equity70

Profit margins14

EBIT Margin1

Gross Profitability26

Cash backing39

Accruals22

Owner Earnings Margin55

Growth40

Sales growth34

Profit growth6

Reinvestment32

Price momentum69

Safety31

Debt load30

Debt serviceability40

Refinancing79

Debt Payback1

Liquidity19

Sentiment52

Analyst ratings31

Expectations trend57

Opinion Changes50

Price Target Upside63

Market mood37

Value Creation10/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Beam Therapeutics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2017

Employees541

Websitebeamtx.com

ISINUS07373V1052

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

CardiovascularStem Cell TherapyHematologyGenetic DisorderOncologyGeneticsBiotechnologyMedicalTherapeutics

Description

Beam Therapeutics Inc. (Beam), a biotechnology company, is establishing the fully integrated platform for precision genetic medicines. The company’s suite of gene editing technologies is anchored by its proprietary base editing technology, which pot…

Analysis

Middle-of-the-road

Beam Therapeutics Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Beam Therapeutics with its peers

Metagenomi Therapeutics

NSQ:MGX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Solid Biosciences

NSQ:SLDB

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Voyager Therapeutics

NSQ:VYGR

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Benitec Biopharma

NAQ:BNTC

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Pacific Biosciences of California

NSQ:PACB

CountryUSA

IndustryLife Sciences Tools & Services

SizeSmall

Full Stock Analysis →

Jade Biosciences

NAQ:JBIO

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →